Macrophage colony-stimulating factor and cancer: a review

Tumor Biology

Volumn 35, Issue 11, 2014, Pages 10635-10644

  Chockalingam, S ^a   Ghosh, Siddhartha Sankar ^a  

^a INDIAN INSTITUTE OF TECHNOLOGY GUWAHATI   (India)

Author keywords

Angiogenesis; Cancer stem cells; Drug resistance; Interleukins; Macrophage colony stimulating factor; Paraptosis; Tumor associated macrophages; Vascular endothelial growth factor

Indexed keywords

COLONY STIMULATING FACTOR 1; MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; RECEPTOR; UNCLASSIFIED DRUG;

HUMAN; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR BIOLOGY; NONHUMAN; PHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; TUMOR ASSOCIATED LEUKOCYTE; ANIMAL; MACROPHAGE; METABOLISM; NEOPLASM; PATHOLOGY;

ANIMALS; HUMANS; MACROPHAGE COLONY-STIMULATING FACTOR; MACROPHAGES; NEOPLASMS;

EID: 84922004528     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-2627-0     Document Type: Review

References (89)

1. Heppner GH. Tumor heterogeneity. Cancer Res. 1984;44(6):2259–65.
2. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883–99. doi:10.1016/j.cell.2010.01.025.
3. Man YG, Stojadinovic A, Mason J, Avital I, Bilchik A, Bruecher B, et al. Tumor-infiltrating immune cells promoting tumor invasion and metastasis: existing theories. J Cancer Educ. 2013;4(1):84–95. doi:10.7150/jca.5482.
4. Movahedi K, Laoui D, Gysemans C, Baeten M, Stange G, Van den Bossche J, et al. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res. 2010;70(14):5728–39. doi:10.1158/0008-5472.can-09-4672.
5. Sica A, Larghi P, Mancino A, Rubino L, Porta C, Totaro MG, et al. Macrophage polarization in tumour progression. Semin Cancer Biol. 2008;18(5):349–55. doi:10.1016/j.semcancer.2008.03.004.
6. de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer. 2006;6(1):24–37. doi:10.1038/nrc1782.
7. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell. 2010;141(1):39–51. doi:10.1016/j.cell.2010.03.014.
8. Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell. 2006;124(2):263–6. doi:10.1016/j.cell.2006.01.007.
9. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer. 2004;4(1):71–8. doi:10.1038/nrc1256.
10. Mantovani A, Sica A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol. 2010;22(2):231–7. doi:10.1016/j.coi.2010.01.009.
11. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002;23(11):549–55.
12. Sica A, Schioppa T, Mantovani A, Allavena P. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer. 2006;42(6):717–27. doi:10.1016/j.ejca.2006.01.003.
13. Riabov V, Gudima A, Wang N, Mickley A, Orekhov A, Kzhyshkowska J. Role of tumor associated macrophages in tumor angiogenesis and lymphangiogenesis. Front Physiol. 2014;5:75. doi:10.3389/fphys.2014.00075.
14. Stanley ER, Berg KL, Einstein DB, Lee PS, Pixley FJ, Wang Y, et al. Biology and action of colony–stimulating factor-1. Mol Reprod Dev. 1997;46(1):4–10. doi:10.1002/(SICI)1098-2795(199701)46:1<4::AID-MRD2>3.0.CO;2-V.
15. Stanley ER, Chen DM, Lin HS. Induction of macrophage production and proliferation by a purified colony stimulating factor. Nature. 1978;274(5667):168–70.
16. Yeung YG, Stanley ER. Proteomic approaches to the analysis of early events in colony-stimulating factor-1 signal transduction. Mol Cell BiolMCP. 2003;2(11):1143–55. doi:10.1074/mcp.R300009-MCP200.
17. Hamilton JA. CSF-1 signal transduction. J Leukoc Biol. 1997;62(2):145–55.
18. Bartelmez SH, Bradley TR, Bertoncello I, Mochizuki DY, Tushinski RJ, Stanley ER, et al. Interleukin 1 plus interleukin 3 plus colony-stimulating factor 1 are essential for clonal proliferation of primitive myeloid bone marrow cells. Exp Hematol. 1989;17(3):240–5.
19. Douglass TG, Driggers L, Zhang JG, Hoa N, Delgado C, Williams CC, et al. Macrophage colony stimulating factor: not just for macrophages anymore! A gateway into complex biologies. Int Immunopharmacol. 2008;8(10):1354–76. doi:10.1016/j.intimp.2008.04.016.
20. Shadle PJ, Aldwin L, Nitecki DE, Koths K. Human macrophage colony-stimulating factor heterogeneity results from alternative mRNA splicing, differential glycosylation, and proteolytic processing. J Cell Biochem. 1989;40(1):91–107. doi:10.1002/jcb.240400110.
21. Cerretti DP, Wignall J, Anderson D, Tushinski RJ, Gallis BM, Stya M, et al. Human macrophage-colony stimulating factor: alternative RNA and protein processing from a single gene. Mol Immunol. 1988;25(8):761–70.
22. Wang ZE, Myles GM, Brandt CS, Lioubin MN, Rohrschneider L. Identification of the ligand-binding regions in the macrophage colony-stimulating factor receptor extracellular domain. Mol Cell Biol. 1993;13(9):5348–59.
23. Stein J, Borzillo GV, Rettenmier CW. Direct stimulation of cells expressing receptors for macrophage colony-stimulating factor (CSF-1) by a plasma membrane-bound precursor of human CSF-1. Blood. 1990;76(7):1308–14.
24. Roussel MF. Signal transduction by the macrophage-colony-stimulating factor receptor (CSF-1R). J Cell Sci Suppl. 1994;18:105–8.
25. Bourette RP, Rohrschneider LR. Early events in M-CSF receptor signaling. Growth Factors. 2000;17(3):155–66.
26. van der Geer P, Hunter T. Mutation of Tyr697, a GRB2-binding site, and Tyr721, a PI 3-kinase binding site, abrogates signal transduction by the murine CSF-1 receptor expressed in Rat-2 fibroblasts. EMBO J. 1993;12(13):5161–72.
27. Reedijk M, Liu X, van der Geer P, Letwin K, Waterfield MD, Hunter T, et al. Tyr721 regulates specific binding of the CSF-1 receptor kinase insert to PI 3′-kinase SH2 domains: a model for SH2-mediated receptor-target interactions. EMBO J. 1992;11(4):1365–72.
28. Bourette RP, Myles GM, Choi JL, Rohrschneider LR. Sequential activation of phoshatidylinositol 3-kinase and phospholipase C-gamma2 by the M-CSF receptor is necessary for differentiation signaling. EMBO J. 1997;16(19):5880–93. doi:10.1093/emboj/16.19.5880.
29. Novak U, Nice E, Hamilton JA, Paradiso L. Requirement for Y706 of the murine (or Y708 of the human) CSF-1 receptor for STAT1 activation in response to CSF-1. Oncogene. 1996;13(12):2607–13.
30. Cecchini MG, Dominguez MG, Mocci S, Wetterwald A, Felix R, Fleisch H, et al. Role of colony stimulating factor-1 in the establishment and regulation of tissue macrophages during postnatal development of the mouse. Development. 1994;120(6):1357–72.
31. Evans R, Kamdar SJ, Fuller JA, Krupke DM. The potential role of the macrophage colony-stimulating factor, CSF-1, in inflammatory responses: characterization of macrophage cytokine gene expression. J Leukoc Biol. 1995;58(1):99–107.
32. Warren MK, Ralph P. Macrophage growth factor CSF-1 stimulates human monocyte production of interferon, tumor necrosis factor, and colony stimulating activity. J Immunol. 1986;137(7):2281–5.
33. Sweet MJ, Hume DA. CSF-1 as a regulator of macrophage activation and immune responses. Arch Immunol Ther Exp. 2003;51(3):169–77.
34. Ryan GR, Dai XM, Dominguez MG, Tong W, Chuan F, Chisholm O, et al. Rescue of the colony-stimulating factor 1 (CSF-1)-nullizygous mouse (Csf1(op)/Csf1(op)) phenotype with a CSF-1 transgene and identification of sites of local CSF-1 synthesis. Blood. 2001;98(1):74–84.
35. Wiktor-Jedrzejczak W, Bartocci A, Ferrante Jr AW, Ahmed-Ansari A, Sell KW, Pollard JW, et al. Total absence of colony-stimulating factor 1 in the macrophage-deficient osteopetrotic (op/op) mouse. Proc Natl Acad Sci U S A. 1990;87(12):4828–32.
36. Michaelson MD, Bieri PL, Mehler MF, Xu H, Arezzo JC, Pollard JW, et al. CSF-1 deficiency in mice results in abnormal brain development. Development. 1996;122(9):2661–72.
37. Pollard JW, Hennighausen L. Colony stimulating factor 1 is required for mammary gland development during pregnancy. Proc Natl Acad Sci U S A. 1994;91(20):9312–6.
38. Pollard JW, Hunt JS, Wiktor-Jedrzejczak W, Stanley ER. A pregnancy defect in the osteopetrotic (op/op) mouse demonstrates the requirement for CSF-1 in female fertility. Dev Biol. 1991;148(1):273–83.
39. Behnes CL, Bremmer F, Hemmerlein B, Strauss A, Strobel P, Radzun HJ. Tumor-associated macrophages are involved in tumor progression in papillary renal cell carcinoma. Virchows Arch: Int J Pathol. 2014;464(2):191–6. doi:10.1007/s00428-013-1523-0.
40. Kacinski BM, Scata KA, Carter D, Yee LD, Sapi E, King BL, et al. FMS (CSF-1 receptor) and CSF-1 transcripts and protein are expressed by human breast carcinomas in vivo and in vitro. Oncogene. 1991;6(6):941–52.
41. Ramakrishnan S, Xu FJ, Brandt SJ, Niedel JE, Bast Jr RC, Brown EL. Constitutive production of macrophage colony-stimulating factor by human ovarian and breast cancer cell lines. J Clin Invest. 1989;83(3):921–6. doi:10.1172/jci113977.
42. Kacinski BM, Carter D, Mittal K, Yee LD, Scata KA, Donofrio L, et al. Ovarian adenocarcinomas express fms-complementary transcripts and fms antigen, often with coexpression of CSF-1. Am J Pathol. 1990;137(1):135–47.
43. Kacinski BM. CSF-1 and its receptor in ovarian, endometrial and breast cancer. Ann Med. 1995;27(1):79–85.
44. Mroczko B, Groblewska M, Wereszczynska-Siemiatkowska U, Okulczyk B, Kedra B, Laszewicz W. Serum macrophage-colony stimulating factor levels in colorectal cancer patients correlate with lymph node metastasis and poor prognosis. Clin Chim Acta; Int J Clin Chem. 2007;380(1–2):208–12.
45. Groblewska M, Mroczko B, Wereszczynska-Siemiatkowska U, Mysliwiec P, Kedra B, Szmitkowski M. Serum levels of granulocyte colony-stimulating factor (G-CSF) and macrophage colony-stimulating factor (M-CSF) in pancreatic cancer patients. Clin Chem Lab Med: CCLM / FESCC. 2007;45(1):30–4. doi:10.1515/CCLM.2007.025.
46. McDermott RS, Deneux L, Mosseri V, Vedrenne J, Clough K, Fourquet A, et al. Circulating macrophage colony stimulating factor as a marker of tumour progression. Eur Cytokine Netw. 2002;13(1):121–7.
47. Chambers SK, Kacinski BM, Ivins CM, Carcangiu ML. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1. Clini Cancer Res: Off J Am Assoc Cancer Res. 1997;3(6):999–1007.
48. Richards DM, Hettinger J, Feuerer M. Monocytes and macrophages in cancer: development and functions. Cancer Microenviron: Off J Int Cancer Microenviron Soc. 2013;6(2):179–91. doi:10.1007/s12307-012-0123-x.
49. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res. 2006;66(2):605–12. doi:10.1158/0008-5472.CAN-05-4005.
50. Lin EY, Nguyen AV, Russell RG, Pollard JW. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Experiment Med. 2001;193(6):727–40.
51. Coffelt SB, Hughes R, Lewis CE. Tumor-associated macrophages: effectors of angiogenesis and tumor progression. Biochim Biophys Acta. 2009;1796(1):11–8. doi:10.1016/j.bbcan.2009.02.004.
52. Murdoch C, Giannoudis A, Lewis CE. Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. Blood. 2004;104(8):2224–34. doi:10.1182/blood-2004-03-1109.
53. Lewis C, Murdoch C. Macrophage responses to hypoxia: implications for tumor progression and anti-cancer therapies. Am J Pathol. 2005;167(3):627–35. doi:10.1016/S0002-9440(10)62038-X.
54. Harmey JH, Dimitriadis E, Kay E, Redmond HP, Bouchier-Hayes D. Regulation of macrophage production of vascular endothelial growth factor (VEGF) by hypoxia and transforming growth factor beta-1. Ann Surg Oncol. 1998;5(3):271–8.
55. Schoppmann SF, Birner P, Stockl J, Kalt R, Ullrich R, Caucig C, et al. Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am J Pathol. 2002;161(3):947–56. doi:10.1016/S0002-9440(10)64255-1.
56. Mantovani A, Schioppa T, Porta C, Allavena P, Sica A. Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev. 2006;25(3):315–22. doi:10.1007/s10555-006-9001-7.
57. Bachelder RE, Wendt MA, Mercurio AM. Vascular endothelial growth factor promotes breast carcinoma invasion in an autocrine manner by regulating the chemokine receptor CXCR4. Cancer Res. 2002;62(24):7203–6.
58. Soker S, Kaefer M, Johnson M, Klagsbrun M, Atala A, Freeman MR. Vascular endothelial growth factor-mediated autocrine stimulation of prostate tumor cells coincides with progression to a malignant phenotype. Am J Pathol. 2001;159(2):651–9. doi:10.1016/S0002-9440(10)61736-1.
59. Plate KH, Breier G, Weich HA, Mennel HD, Risau W. Vascular endothelial growth factor and glioma angiogenesis: coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms. Int J Cancer J Int du Cancer. 1994;59(4):520–9.
60. Boocock CA, Charnock-Jones DS, Sharkey AM, McLaren J, Barker PJ, Wright KA, et al. Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. J Natl Cancer Inst. 1995;87(7):506–16.
61. Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res. 1995;55(18):3964–8.
62. Yoshiji H, Kuriyama S, Hicklin DJ, Huber J, Yoshii J, Miyamoto Y. KDR/Flk-1 is a major regulator of vascular endothelial growth factor-induced tumor development and angiogenesis in murine hepatocellular carcinoma cells. Hepatol (Baltim, Md). 1999;30(5):1179–86. doi:10.1002/hep.510300509.
63. Eubank TD, Galloway M, Montague CM, Waldman WJ, Marsh CB. M-CSF induces vascular endothelial growth factor production and angiogenic activity from human monocytes. J Immunol. 2003;171(5):2637–43.
64. Curry JM, Eubank TD, Roberts RD, Wang Y, Pore N, Maity A, et al. M-CSF signals through the MAPK/ERK pathway via Sp1 to induce VEGF production and induces angiogenesis in vivo. PLoS ONE. 2008;3(10):e3405. doi:10.1371/journal.pone.0003405.
65. Chambers SK, Wang Y, Gertz RE, Kacinski BM. Macrophage colony-stimulating factor mediates invasion of ovarian cancer cells through urokinase. Cancer Res. 1995;55(7):1578–85.
66. Kawakami Y, Nagai N, Ohama K, Zeki K, Yoshida Y, Kuroda E, et al. Macrophage-colony stimulating factor inhibits the growth of human ovarian cancer cells in vitro. Eur J Cancer. 2000;36(15):1991–7.
67. Jadus MR, Irwin MC, Irwin MR, Horansky RD, Sekhon S, Pepper KA, et al. Macrophages can recognize and kill tumor cells bearing the membrane isoform of macrophage colony-stimulating factor. Blood. 1996;87(12):5232–41.
68. Jadus MR, Chen Y, Boldaji MT, Delgado C, Sanchez R, Douglass T, et al. Human U251MG glioma cells expressing the membrane form of macrophage colony-stimulating factor (mM-CSF) are killed by human monocytes in vitro and are rejected within immunodeficient mice via paraptosis that is associated with increased expression of three different heat shock proteins. Cancer Gene Ther. 2003;10(5):411–20. doi:10.1038/sj.cgt.7700583.
69. Jadus MR, Williams CC, Avina MD, Ly M, Kim S, Liu Y, et al. Macrophages kill T9 glioma tumor cells bearing the membrane isoform of macrophage colony stimulating factor through a phagocytosis-dependent pathway. J Immunol. 1998;160(1):361–8.
70. Hoa NT, Zhang JG, Delgado CL, Myers MP, Callahan LL, Vandeusen G. Human monocytes kill M-CSF-expressing glioma cells by BK channel activation. Laboratory investigation. J Tech Methods Pathol. 2007;87(2):115–29. doi:10.1038/labinvest.3700506.
71. Chockalingam S, Ghosh SS. Amelioration of cancer stem cells in macrophage colony stimulating factor-expressing U87MG-human glioblastoma upon 5-fluorouracil therapy. PLoS ONE. 2013;8(12):e83877. doi:10.1371/journal.pone.0083877.
72. McConkey DJ, Choi W, Marquis L, Martin F, Williams MB, Shah J, et al. Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer. Cancer Metastasis Rev. 2009;28(3–4):335–44. doi:10.1007/s10555-009-9194-7.
73. Bao B, Wang Z, Ali S, Kong D, Li Y, Ahmad A, et al. Notch-1 induces epithelial-mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells. Cancer Lett. 2011;307(1):26–36. doi:10.1016/j.canlet.2011.03.012.
74. Arumugam T, Ramachandran V, Fournier KF, Wang H, Marquis L, Abbruzzese JL, et al. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res. 2009;69(14):5820–8. doi:10.1158/0008-5472.can-08-2819.
75. Galdiero MR, Garlanda C, Jaillon S, Marone G, Mantovani A. Tumor associated macrophages and neutrophils in tumor progression. J Cell Physiol. 2013;228(7):1404–12. doi:10.1002/jcp.24260.
76. Cook J, Hagemann T. Tumour-associated macrophages and cancer. Curr Opin Pharmacol. 2013;13(4):595–601. doi:10.1016/j.coph.2013.05.017.
77. Santoni M, Massari F, Amantini C, Nabissi M, Maines F, Burattini L, et al. Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma. Cancer Immunol, Immunother: CII. 2013;62(12):1757–68. doi:10.1007/s00262-013-1487-6.
78. Rego SL, Helms RS, Dreau D. Tumor necrosis factor-alpha-converting enzyme activities and tumor-associated macrophages in breast cancer. Immunol Res. 2014;58(1):87–100. doi:10.1007/s12026-013-8434-7.
79. Tang X. Tumor-associated macrophages as potential diagnostic and prognostic biomarkers in breast cancer. Cancer Lett. 2013;332(1):3–10. doi:10.1016/j.canlet.2013.01.024.
80. Jarnicki AG, Lysaght J, Todryk S, Mills KH. Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells. J Immunol. 2006;177(2):896–904.
81. Kuang DM, Zhao Q, Peng C, Xu J, Zhang JP, Wu C, et al. Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. J Exp Med. 2009;206(6):1327–37. doi:10.1084/jem.20082173.
82. Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong H, Webster WS, et al. Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A. 2004;101(49):17174–9. doi:10.1073/pnas.0406351101.
83. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A. 2002;99(19):12293–7. doi:10.1073/pnas.192461099.
84. Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A. 2007;104(9):3360–5. doi:10.1073/pnas.0611533104.
85. Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol. 2010;11(10):889–96. doi:10.1038/ni.1937.
86. Hagemann T, Lawrence T, McNeish I, Charles KA, Kulbe H, Thompson RG, et al. “Re-educating” tumor-associated macrophages by targeting NF-kappaB. J Exp Med. 2008;205(6):1261–8. doi:10.1084/jem.20080108.
87. Guiducci C, Vicari AP, Sangaletti S, Trinchieri G, Colombo MP. Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res. 2005;65(8):3437–46. doi:10.1158/0008-5472.CAN-04-4262.
88. Watkins SK, Egilmez NK, Suttles J, Stout RD. IL-12 rapidly alters the functional profile of tumor-associated and tumor-infiltrating macrophages in vitro and in vivo. J Immunol. 2007;178(3):1357–62.
89. Stout RD, Watkins SK, Suttles J. Functional plasticity of macrophages: in situ reprogramming of tumor-associated macrophages. J Leukoc Biol. 2009;86(5):1105–9. doi:10.1189/jlb.0209073.